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expensive with leuprolide in Commercial plans. If full compliance is achieved, cost
of treatment is lower with histrelin implants in bothmarkets. The additional med-
ical cost of non-compliance was not included in this model.
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OBJECTIVES: We sought to evaluate the impact of diabetes prevention costs and
effectiveness on the projected return on investment (ROI) from the perspectives of
a US health care payer and a large, self-insured employer using an improved risk
stratification tool. METHODS: A model comprised of a closed cohort with four
Markov health-states was developed to project diabetes-specific costs and offsets
due to incident diabetes and utilization of prevention resources. Subjects identified
as “at-risk” for diabetes in an annual health risk appraisal would be tested and
stratified into high or moderate-to-low risk groups. Parameters of the screen for
at-risk subjects were based upon published impaired fasting plasma glucose prev-
alence of an insured US population. High risk subjects optionally enter a diabetes
prevention program. Parameters for the risk stratification test were based upon
published data for a multiple biomarker risk assessment test (PreDx DRS). Cost
inputs included direct and indirect medical costs of diabetes and pre-diabetes, and
the cost of stratification testing ($250). A range of intervention costs and effective-
nesswere examined.Model outputs included projected costs, savings, and number
of life years and diabetes-free years saved. RESULTS: At a published annual pre-
vention program cost of $850 and intervention effectiveness of 58%, employers
would see a positive ROI by year 2 that increases through year 5. Savings at year 5
represent a return of $1.71 for every $1 spent on diabetes prevention, with 167
diabetes cases prevented, 547 diabetes-free years and 6.3 life years saved per 10,000
employees. Payers could achieve cost savings at lower program costs and/or in-
creased effectiveness. The ROI depends strongly on reported intervention effec-
tiveness in the range of 31%-72% and is moderately sensitive to cost variations.
CONCLUSIONS: Cost savings for employers and payers are possible using risk
stratification in conjunction with an effective prevention program to reduce dia-
betes incidence.
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OBJECTIVES: Hypervolemic hyponatremia (HN) is commonly found in patients
with decompensated cirrhosis and is associated with increasedmortality, morbid-
ity and longer hospital stays. Despite its prevalence in hospitalized patients (15-
30%), little is known of the effect of HN on cirrhotic patients in terms of resource
utilization. The present study was designed to explore the impact of HN on cost,
length of stay (LOS), ICU admission and 30, 90, 180-day readmission in hospitalized
cirrhotic patients.METHODS: The Premier hospital database was utilized to iden-
tify US hospital inpatients discharged between January 1, 2007 and June 30, 2009.
Hyponatremic cirrhotic patients were identified using primary or secondary ICD-
9-CM codes and were matched to a control group using exact matching on age,
gender, provider region and MS-DRG assignment. Matching was further refined
using propensity scores based on additional patient and hospital covariates. The
final analytic sample contained 3,765 cirrhotic hyponatremia patients and 25,549
cirrhotic non-hyponatremia patients. Cost was analyzed using gamma regression,
LOS with negative binomial regression. ICU admission and hospital readmission
were analyzed using multivariate logistic regression. RESULTS: In contrast to non-
hyponatremic cirrhotic patients, hyponatremic patients with cirrhosis had signif-
icantly higher total inpatient cost (80.56%, CI61.95-101.31; p0.0001), ICU cost
(64.36%; CI38.51-95.01; p.0001), total LOS (63.10%, CI52.96-73.92; p0.0001),
and ICU LOS (62.39%, CI40.26-88.02; p.0001). Hyponatremic cirrhotic patients
were significantly more likely to be admitted to the ICU (OR2.10; p0.0001) and
readmitted at 30- (OR1.38; p0.0003), 90- (OR1.26; p0.0025), and 180-days
(OR1.25; p0.0026) in comparison with non-hyponatremic cirrhotic patients.
CONCLUSIONS: The presence of HN in hospitalized cirrhotic patients is signifi-
cantly associated with increased total and ICU cost and LOS, likelihood of ICU
admission and 30, 90, 180-day readmission.
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OBJECTIVES: A common challenge in the management of type 2 diabetes is to
achieve glycemic control while avoiding side effects, such as weight gain and hy-
poglycemia. Assessing the cost of achieving a clinically relevant composite end-
point of HbA1c7%, no weight gain, and no hypoglycemia may be useful for eval-
uation and comparison of diabetes treatments. The objective of this study is to
estimate the cost per successfully treated patient, to this composite endpoint,
when treated with either liraglutide 1.8mg once-daily or exenatide 10g
twice-daily. METHODS: A recently conducted meta-analysis (Zinman et al. 2012)
estimated the percentage of patients achieving the composite endpoint of
HbA1c7%, no weight gain and no hypoglycemia for liraglutide versus comparator
therapies and placebo. The cost per successfully treated patient for liraglutide
1.8mg and exenatide 10g was calculated as the total acquisition costs over 26
weeks (incl. cost of needles) divided by the percentage of patients reaching the
composite endpoint. RESULTS: After 26 weeks, 40% of patients treated with lira-
glutide 1.8mg (n1,513) were estimated to reach the clinically relevant triple com-
posite endpoint versus 25% when treated with exenatide 10g (n186) (p0.001).
Over 26weeks the calculated costs per successfully treated patientwere lowerwith
liraglutide 1.8mg once-daily ($6641) than exenatide 10g twice-daily ($7535).
CONCLUSIONS:When relating the cost of treatment directly to a clinically relevant
composite outcome, as defined by the percentage of patients reaching an HbA1c
target below 7%, noweight gain and no hypoglycemia, liraglutide 1.8mg once-daily
showed lower costs per successfully treated patient than exenatide 10g twice-
daily, over a 26-week period.
PDB34
REAL-WORLD HEALTH CARE UTILIZATION, PRODUCTIVITY AND ASSOCIATED
COSTS AMONG EMPLOYEES WITH TYPE 2 DIABETES MELLITUS TREATED WITH
INSULIN GLARGINE OR NEUTRAL PROTAMINE HAGEDORN (NPH) INSULIN IN
THE UNITED STATES
Wang L1, Wei W2, Miao R3, Xie L4, Baser O4
1STATinMED Research, Dallas, TX, USA, 2Sanofi-Aventis U.S., Bridgewater, NJ, USA, 3Sanofi-
Aventis, Bridgewater, NJ, USA, 4STATinMED Research/The University of Michigan, Ann Arbor,
MI, USA
OBJECTIVES: To assess real-world outcomes among US employees with type 2
diabetes mellitus (T2DM) initiating insulin therapy via insulin glargine (GLA) or
NPH insulin.METHODS: This retrospective analysis used MarketScan® databases
to identify employeeswith T2DMwho initiated GLA or NPH, had continuous health
plan and short-term-disability (STD) coverage for 3-month pre- (baseline) and
1-year post-initiation (follow-up), were insulin-naïve but received 1 oral anti-
diabetes drug (OAD) and/or glucagon-like peptide-1 during baseline period. End-
points included 1-year treatment persistence (continuous study drug use without
discontinuation) and adherence (adjusted medication possession ratio), hypogly-
cemia, healthcare utilization and costs, STDand associated cost. Observed baseline
selection bias between these two cohorts was addressed by 2:1 propensity score
matching (PSM). RESULTS: A total of 534 patients (GLA: 356, NPH: 178) were
matched and analyzed (women 43.8%; baseline mean age 49 year; hospitalization
15.3%; # of OADs 1.8; STD: 3.0 days). During follow-up, patients receiving GLA,
comparing to NPH, were significantly more persistent and adherent (both P0.05),
had lower rates of hospitalization (23.0% vs. 31.4%; P0.036) and endocrinologist
visits (19.1% vs. 26.9%; P0.038), similar hypoglycemia-related event rates (both
4.4%; P1.0), higher diabetes drug costs ($1,915 vs. $1,442; P0.001) but similar total
overall healthcare costs ($13,822 vs. $15,170; P0.488) and total diabetes-related
health care costs ($4,474 vs $5,235; P0.466). STD days and associated cost were
marginally lower for GLA than NPH (16.0 vs. 24.5 days, $2,680 vs. $4,118; both
P0.086). Sensitivity analyses using 1:1 and 3:1 PSM yielded consistent results.
CONCLUSIONS: This study suggested that among US employees with T2DM
initiating insulin, compared to NPH, GLA was associated with improved persis-
tence and adherence and similar direct health care cost despite higher drug
costs. GLA was also associated with lower hospitalization rate, which further
led to shorter STD days and associated cost, and might help improve workplace
productivity.
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OBJECTIVES: Randomized clinical trials, SALT-1 and SALT-2, showed that tolvap-
tan was an efficacious and safe therapy for the treatment of hyponatremic SIADH
(Syndrome of Inappropriate Antidiuretic Hormone Secretion) and was associated
with a reduction in the length of stay (LOS) in the hospital for SIADH patients. This
study evaluated the medical cost offsets associated with tolvaptan usage based on
the SALT-1 and SALT-2 trials.METHODS: The Healthcare Cost and Utilization Proj-
ect (HCUP) 2009 Nationwide Inpatient Sample (NIS) database was used to estimate
LOS and hospital cost of SIADH patients (age18 years) in the United States. A cost
offset model was constructed and utilized to evaluate the impact of tolvaptan on
hospital cost and LOS, with univariate and multivariate Monte Carlo sensitivity
analyses. RESULTS: In the SALT-1 and SALT-2 trials, SIADH patients receiving
tolvaptan had a shorter hospital LOS than placebo patients (4.98 vs. 6.19 days).
From the HCUPNIS database, 21,718 SIADH hospitalizationswere identified, with a
mean LOS of 5.7 days andmeanhospital costs of $8667.With an inpatient tolvaptan
treatment duration of 4 days, the cost offset model estimated that tolvaptan usage
was associated with amean LOS reduction of 1.1 days and a hospital cost saving of
$694 per admission. The cost reduction ranged from $355 to $1033 with variations
of any singlemodeling parameter. 10,000 cycles of Monte Carlo simulation showed
the 95% confidence interval for cost saving to be $73$1,405, with 98.8% cycles
having a positive net cost saving. The total cost saving was estimated to be $15
million among the HCUP/SIADH population. CONCLUSIONS: Based on the SALT-1
and SALT-2 trials, tolvaptan usage versus placebo is associated with a shorter
hospital LOS. This study showed that tolvaptan usage versus placebo is addition-
ally associated with lower hospital costs among hyponatremic SIADH patients in
the United States.
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